Toxic mixes making it harder to treat street drug overdoses, front-line workers warn
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
an hour ago
- CTV News
Special air quality statement remains in effect across Ontario
Playing null of undefined How poor air quality affects your short-term and long-term health Here's what you need to know as smoke continues to impact air quality across the country Special air quality statement issued for Toronto and GTA
CBC
2 hours ago
- CBC
Tick-borne diseases on rise due to warmer temperatures, experts say
With warmer weather, Health Canada is warning about the growing risk of tick-borne illnesses like Lyme disease now spreading to new regions. Dr. Christopher Labos weighs in and also talks about staying safe amid widespread air quality alerts due to wildfire smoke.
Globe and Mail
3 hours ago
- Globe and Mail
How Did Skyrizi and Rinvoq Sales Contribute to AbbVie's Q2 Results?
AbbVie ABBV delivered encouraging second-quarter 2025 results last week, sending a clear message — it is effectively managing its post-Humira transition. The stronger-than-expected sales of newer immunology medicines, Rinvoq and Skyrizi, not only mitigated the impact of Humira's continued erosion but also reaffirmed their role as growth drivers for AbbVie. Skyrizi sales rose 62% year over year on an operational basis to $4.42 billion, while Rinvoq sales added $2.03 billion, up 41%. These upsides were driven by strong volume growth and continued market share gains across all approved indications, especially in the popular inflammatory bowel disease (IBD) space, which includes two conditions — ulcerative colitis (UC) and Crohn's disease (CD). In its Q2 conference call, AbbVie emphasized the continued robust uptake of both drugs in IBD, noting that Skyrizi and Rinvoq together hold roughly half of the in-place market share in CD and nearly one-third of the in-play share in UC. AbbVie expects to return to growth in 2025, driven by the robust performance of Skyrizi and Rinvoq, despite it being only the second year following the U.S. Humira LOE. It expects combined sales of these two drugs to cross $25 billion in 2025. AbbVie raised its Skyrizi sales guidance by $600 million to $17.1 billion, driven by continued share gains in psoriasis and IBD. Rinvoq sales remain on track to reach around $8.2 billion for the year. The upward revision in Skyrizi guidance more than offsets the reduced outlook for Humira guidance. AbbVie now expects U.S. Humira revenues to be $3 billion, down from the prior expectation of $3.5 billion due to higher erosion from biosimilar competition as well as further molecule compression. ABBV's Peers in the Immunology Space The targeted market is highly competitive. A key player in this field is Johnson & Johnson JNJ, which markets two blockbuster drugs — Stelara and Tremfya. Both of these J&J medications are approved for multiple immunology indications, including UC and CD. Since Stelara lost U.S. patent exclusivity earlier this year, J&J has shifted its focus to Tremfya to maintain its market position. Another pharma giant expanding its presence in immunology is Eli Lilly LLY, following the FDA approval of Omvoh for the UC indication in late 2023. Omvoh marked Lilly's first immunology drug approved for a type of IBD in the United States, playing a key role in expanding its portfolio in this therapeutic area. The Lilly drug received FDA approval for the CD indication in January. ABBV's Price Performance, Valuation and Estimates Shares of AbbVie have outperformed the industry year to date, as seen in the chart below. From a valuation standpoint, AbbVie is trading at a premium to the industry. Based on the price/earnings (P/E) ratio, the company's shares currently trade at 14.58 times forward earnings, a tad higher than its industry's average of 14.28. The stock is also trading above its five-year mean of 12.61. Bottom-line estimate movements for 2025 and 2026 have been mixed over the past 7 days. AbbVie currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Zacks Names #1 Semiconductor Stock This under-the-radar company specializes in semiconductor products that titans like NVIDIA don't build. It's uniquely positioned to take advantage of the next growth stage of this market. And it's just beginning to enter the spotlight, which is exactly where you want to be. With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $971 billion by 2028. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report
